Search company, investor...

Biomedical Diagnostics

Founded Year



Acquired | Acquired

About Biomedical Diagnostics

On June 13th, 2022, Biomedical Diagnostics was acquired by Eurobio Scientific. The terms of the transaction were not disclosed. Biomedical Diagnostics (BMD) is a Belgian company marketing specialty tests for medical diagnostics. It specializes in the distribution of in vitro diagnostic tests in Benelux (Belgium, the Netherlands and Luxembourg). The company was founded in 1986 and is based in Antwerp, Belgium.

Headquarters Location

Ahlers House Noorderlaan 139

Antwerp, 2030,


+32 (0)3 546 39 80

Missing: Biomedical Diagnostics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Biomedical Diagnostics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Biomedical Diagnostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biomedical Diagnostics is included in 1 Expert Collection, including Medical Devices.


Medical Devices

8,633 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Latest Biomedical Diagnostics News

Drug Screening Market | Bio-Rad Laboratories Inc., Biomedical Diagnostics, Danaher, Synergy Health plc. | By 2033

Apr 10, 2023

| By 2033 The Drug Screening Market is likely to thrive at a strong CAGR of 15.1% between 2023 and 2033. The market is anticipated to cross a market share of US$ 32.4 billion by 2033 while it is valued at US$ 7.3 billion in 2023. There are more and more people using drugs of all kinds, and there are also more and more treatment centres, according to a study report on the drug screening sector. Sales of drug screening technologies are also increasing as a result of the new government restrictions that prohibit drug use and drug trafficking. The distribution of narcotics by drug users who support violence and drug abuse is under pressure from authorities to be restricted. Prescription drug abuse and black market sales are driving up demand for drug screening devices. Furthermore, there is a growing interest in creating drug screening tools that are more effective and efficient. The rise in young people’s usage of recreational drugs is driving up demand for advanced drug screening devices. Request Sample Report: More adult people indulging in drug consumption, and Islamic countries banning alcohol consumption is fueling the drug screening market. Furthermore, advanced screening and testing measures are pushing governments to adopt screening equipment. Enhancing high-throughput screening to discover early-strange drug discovery is expanding the drug screening market size, while additional high-content screening (HCS) is also contributing to the growth of the market. Another factor that fuels the market growth is the adoption of fragment-based drug discovery (FBDD) with the bottom-up approach that works on low-complexity compounds or fragments. The advanced offices and corporate structure include drug testing and screening solutions that also help the workforce to be clean and conscious. The governments in some countries also push corporate companies to adopt these measures for drug control. The misuse of prescribed drugs and their trafficking has also fueled the demand for different drug control measures, flourishing the drug screening market. Ask An Analyst@ Key Points The United States market leads the space in terms of market share and CAGR. The market is anticipated to cross a value of US$ 11.5 billion by 2033. The regional market is expected to thrive at a CAGR of 15.8% between 2023 and 2033. The Chinese drug screening market is another significant market. It thrives at a steady CAGR of 15.4% during the forecast period. The market is likely to reach a value of US$ 2.3 billion by 2033. The prevalence of drug consumption and stringent government policies are fueling the demand for drug screening. Rapid testing devices are likely to thrive in the product and service type category due to faster and more efficient drug testing methods. It is expected to thrive at a CAGR of 15.8% during the forecast period. The drug testing devices laboratories segment tops the end user tally with a CAGR of 15.4% between 2023 and 2033. The growth is attributed to higher consumption and lack of drug testing equipment in the organizations due to the lower awareness. Competitive Landscape The key players focus on providing drug screening solutions at cheaper prices while making these products portable, efficient, and effective. Key competitors also merge, acquire, and partner with other companies to increase the supply chain and distribution channel. The key players in the market are: Laboratory Corporation of America Holdings, Hoffmann -La Roche Ltd, BioMerieux SA, Bio-Rad Laboratories Inc., Biomedical Diagnostics For instance: Bio-Rad Laboratories Inc has introduced its Bio-Rad which works on different concepts such as target discovery, lead discovery, preclinical research, and Progress development. This has extended the research and development programs for the brand. BioMerieux SA has completed its 60 years in the service. This has resulted in the biomerieux and InDevR partnership of 5 million. This will be the exclusive distributor in Europe of VaxArray. Key Segments Hospitals

Biomedical Diagnostics Frequently Asked Questions (FAQ)

  • When was Biomedical Diagnostics founded?

    Biomedical Diagnostics was founded in 1986.

  • Where is Biomedical Diagnostics's headquarters?

    Biomedical Diagnostics's headquarters is located at Ahlers House, Antwerp.

  • What is Biomedical Diagnostics's latest funding round?

    Biomedical Diagnostics's latest funding round is Acquired.

  • Who are the investors of Biomedical Diagnostics?

    Investors of Biomedical Diagnostics include Eurobio Scientific.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.